Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom in MASH and HFpEF
NCT07830758Phase 1Recruiting
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Arm 1 - Resmetirom with Arm 2 - Placebo Comparator (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent serious adverse events and 17 more. Started Sep 2026; status: recruiting.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07830758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830758.